Celgene CEO Alles scored $3M raise in 2018 despite slip-ups by Arlene Weintraub Tuesday, March 5, 2019 Celgene said CEO Mark Alles hit financial and regulatory milestones to win a hefty 2018 bonus, but investors were focused on the company's troubles.
Revlimid generics hit Europe just as Celgene's enjoying U.S. win by Eric Sagonowsky Wednesday, February 13, 2019 Only days after Celgene dodged a U.S. patent attack on its megablockbuster drug Revlimid, a copycat has rolled onto the market in Europe.
Good news for BMS: Celgene’s Revlimid clears patent challenge by Eric Sagonowsky Tuesday, February 12, 2019 Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.
BMS talks up Celgene merger to divert Opdivo disappointment by Arlene Weintraub Thursday, January 24, 2019 BMS execs faced a tough audience during its Q4 report, as analysts pressed them for details about how the Celgene merger would drive growth.
BMS-Celgene merger will raise drug prices, U.S. congressmen say by Arlene Weintraub Tuesday, January 15, 2019 Past pharma mergers have spawned price hikes, two U.S. representatives argue—and DTC and DOJ need to weigh the $74 billion deal with that in mind.
Revlimid pitfalls overshadow oncology wins in BMS-Celgene deal by Arlene Weintraub Friday, January 4, 2019 New cancer drugs in the BMS-Celgene pipeline won't be enough to cover an earlier-than expected Revlimid patent loss, analysts say.
BMS scores first big deal of 2019 with $74B Celgene buyout by Arlene Weintraub Thursday, January 3, 2019 BMS's buyout of Celgene values it at $102.43 a share—54% higher than its closing price on Wednesday evening.
Celgene lines up for $600M Revlimid boost with lymphoma win by Carly Helfand Friday, November 2, 2018 Celgene’s Revlimid may have slipped in previously untreated follicular lymphoma. But in the second-line setting, the drug has a win.
Celgene posts volume-driven growth in Q2 by Eric Sagonowsky Thursday, July 26, 2018 Celgene is extracting volume-driven sales growth as the entire industry has come under scrutiny for its pricing.
